Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E.W. Cohen, Signe Friesland, Lisa Licitra et al.|The Lancet|2018Cited by 1.7k
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckKevin J. Harrington, Robert I. Haddad, Robert L. Ferris et al.|JAMA Oncology|2023Cited by 73